论文部分内容阅读
目的比较树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗配合化疗与单纯化疗一线治疗卵巢癌的疗效、不良反应及生存质量。方法 54例经病理或细胞学证实的晚期卵巢癌患者,随机分为治疗组和对照组,每组27例。治疗组采用紫杉醇+卡铂联合化疗,并于化疗间歇期配合DCCIK细胞免疫治疗;对照组仅进行紫杉醇+卡铂单纯化疗。观察并比较两组的疗效、不良反应及患者的生存质量。结果治疗组和对照组的有效率分别为55.6%、51.9%,临床获益率分别为92.6%、85.2%,两组比较差异无统计学意义(P>0.05)。治疗组白细胞下降、口腔黏膜炎的发生率均明显低于对照组,差异有统计学意义(P<0.05)。治疗组的Karnofsky评分和生活质量(QOL)评分较对照组有显著提高,差异有统计学意义(P<0.05)。结论 DC-CIK细胞免疫治疗配合化疗与单纯化疗一线治疗晚期卵巢癌比较,疗效相当,但明显减轻化疗的不良反应,显著提高晚期肿瘤患者的生存质量。
Objective To compare the efficacy, adverse reactions and quality of life of first-line dendritic cells-cytokine-induced killer (DC-CIK) immunotherapy combined with chemotherapy and chemotherapy alone. Methods 54 patients with pathologically or cytologically confirmed advanced ovarian cancer were randomly divided into treatment group and control group, with 27 cases in each group. The treatment group with paclitaxel + carboplatin combined with chemotherapy, and in the intermittent chemotherapy with DCCIK cellular immunotherapy; control group only paclitaxel + carboplatin chemotherapy alone. The curative effect, adverse reactions and quality of life of the two groups were observed and compared. Results The effective rates of the treatment group and the control group were 55.6% and 51.9%, respectively. The clinical benefit rates were 92.6% and 85.2% respectively. There was no significant difference between the two groups (P> 0.05). The incidence of leukopenia and oral mucositis in the treatment group was significantly lower than that in the control group (P <0.05). The Karnofsky score and quality of life (QOL) scores of the treatment group were significantly higher than those of the control group, with statistical significance (P <0.05). Conclusion DC-CIK cell immunotherapy with chemotherapy and chemotherapy alone compared with the first-line treatment of advanced ovarian cancer, the curative effect is quite, but significantly reduce chemotherapy adverse reactions, significantly improve the quality of life of patients with advanced cancer.